SPECIAL COVID-19 3 establishments. “Our strategy of opening cen- tres will follow the epidemiological situation of the epidemic with a priority for opening new sites in hospitals under high pressure” she added. This trial willalso complement the data that will be collected as part of another international clinicalt ,rialcalled Solidarity under the auspices of the WHO. Another promising avenue that is explored is the transfusion of antibodies from cured patients to hospitalized patients. A trial called Coviplasm has just started with the Paris hospitals and health care organization AP-HP with the support of Inserm and the French Blood Establishment (EFS). Another initiative great mentioning is the alliance between the Australian CSL Behring, the Japanese Takeda, the German Biotest, the Bristish Bio Products Laboratory (BPL), the French LFB and the Swiss Octapharma to develop a potential plasma-derived therapy for treating Covid-19. The work begins immediately with the inves- tigational development of one, unbranded Due to stock shortages in pharmacies, the French Minister of Health, Olivier anti-SARS-CoV-2 polyclonal hyperimmune Véran, announced the publication of a decree authorizing pharmacists to immunoglobulin medicine with the potential produce until May 31, 2020 their own hydroalcoholic solution, in accor- to treat individuals with serious complications dance with the recommendations of the World Health Organization which from Covid-19. “Unprecedented times call specify the composition, general conditions for preparing, the operating for bold moves,” siad Julie Kim, President mode and the labeling. (photo credit: EMA) of Plasma-Derived Therapies Business Unit, Takeda.“We collectively agree thatby col- third worldwide, behind the United States and laborating and bringing industry resources China. Companies that are extremely involved together, we could accelerate bringing a po- in the field of research are located on French tential therapy to market as well as increase territory with some of their medicines at the the potential supply. We invite companies and heart of clinical trials. In January, all biggest institutions focusing on plasma to support drug companies on the planet immediately or join our alliance.” set up crisis units mobilizing their experts in immunology and viroloy. Soegmdrawn up research plans with biotech companies like The race for vaccine is on GSK allied to the American Vr Biotecnoloyi h g or Sanofi with Regeneron, while others fund With nearly 450 clinical trials launched research teams. Ipsen, for instance, donated worldwide, the pharmaceutical research on 2 million euros to the Institut Pasteur to sup- an emerging pathogen has never been faster. port research on the Covid-19. At Gilead, the Thereis a profusion ofinitiatives particularly manufacturing time for remdesivir (included in France, European champion and ranking in Discovery) has been cut in half. The same